Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

BACKGROUND: The long-term safety was assessed in patients with psoriatic arthritis who were treated with ixekizumab in three clinical trials (SPIRIT-P1/-P2/-P3). METHODS: Integrated safety data from three trials (controlled and uncontrolled), including two pivotal phase 3, randomized, double-blind c...

Descripción completa

Detalles Bibliográficos
Autores principales: Combe, Bernard, Rahman, Proton, Kameda, Hideto, Cañete, Juan D., Gallo, Gaia, Agada, Noah, Xu, Wen, Genovese, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975022/
https://www.ncbi.nlm.nih.gov/pubmed/31964419
http://dx.doi.org/10.1186/s13075-020-2099-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975022/
https://www.ncbi.nlm.nih.gov/pubmed/31964419
http://dx.doi.org/10.1186/s13075-020-2099-0

Ejemplares similares